Bioventus (NYSE:BVS) Updates FY 2025 Earnings Guidance

Bioventus (NYSE:BVS - Get Free Report) updated its FY 2025 earnings guidance on Tuesday. The company provided EPS guidance of 0.640-0.680 for the period, compared to the consensus EPS estimate of 0.660. The company issued revenue guidance of $560.0 million-$570.0 million, compared to the consensus revenue estimate of $564.9 million.

Bioventus Stock Performance

NYSE:BVS traded down $0.10 during mid-day trading on Friday, reaching $6.70. The company's stock had a trading volume of 501,735 shares, compared to its average volume of 452,496. The company has a current ratio of 1.41, a quick ratio of 0.99 and a debt-to-equity ratio of 1.85. The stock has a market cap of $549.02 million, a P/E ratio of -10.98 and a beta of 0.95. The firm's fifty day moving average price is $8.40 and its two-hundred day moving average price is $10.07. Bioventus has a 12-month low of $5.27 and a 12-month high of $14.38.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on BVS shares. Craig Hallum set a $15.00 price objective on shares of Bioventus and gave the company a "buy" rating in a research report on Wednesday. Canaccord Genuity Group reissued a "buy" rating and set a $15.00 price target on shares of Bioventus in a report on Monday, March 17th.

Insider Transactions at Bioventus

In other Bioventus news, SVP Anthony D'adamio sold 4,380 shares of the business's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $10.19, for a total value of $44,632.20. Following the sale, the senior vice president now owns 118,178 shares in the company, valued at $1,204,233.82. The trade was a 3.57 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Mark Leonard Singleton sold 6,498 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $10.19, for a total value of $66,214.62. Following the transaction, the chief financial officer now owns 118,817 shares of the company's stock, valued at $1,210,745.23. This represents a 5.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 24,208 shares of company stock valued at $226,138. 32.90% of the stock is currently owned by corporate insiders.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.